Clinical trials: SARS-CoV-2 Virus Infection
COVID-19, COVID-19 (SARS-CoV-2 Infection)
Evaluation of the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell in Prolonged SARS-CoV-2 Patients
The goal of this clinical study is to evaluate the safety and efficacy of autologous COVID-19 antigen specific T cell (LB-DTK-COV19) treatment in prolonged SARS-CoV-2 infected patients.
- Trial name
- NCT07690943
- Testing
- LB-DTK-COV19
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- LucasBio
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia
Phase II/Phase III study to evaluate the safety and efficacy of Ramatroban 75 mg tablet against Placebo in subjects hospitalized for pneumonia due to SARS-CoV-2 infection.
- Trial name
- NCT05706454
- Testing
- Ramatroban
- Where
- 7 sites in India
- Volunteers
- 324 people
- Sponsor
- KARE Biosciences
SARS CoV 2 Infection
Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects
This is a phase I, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of ASC10 tablets and an open-label, crossover design to evaluate the food effect on PK of ASC10 in…
- Trial name
- NCT05523141
- Testing
- ASC10
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years
The study is a randomized, double-blind, positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E compared with mRNA-1273 (the mRNA COVID-19 vaccine from Moderna) in population aged…
- Trial name
- NCT05345873
- Testing
- SCTV01E, mRNA-1273
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
SARS-CoV-2
Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults
Glycovax Pharma has developed a glycoconjugate vaccine candidate called Glycovax-002 to fight the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the origin of COVID-19.
- Trial name
- NCT05799651
- Testing
- Glycovax-002
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Glycovax Pharma Inc.
SARS-CoV-2
Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
The main goal of this study is to evaluate the outcomes of pregnancy in females exposed to the Moderna COVID-19 vaccine (mRNA-1273) during pregnancy.
- Trial name
- NCT04958304
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
The objective of the study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E, comparing the immunogenicity data against Beta (B.1.351), Delta (B.1.617.2), Omicron (B.1.1.529) and other variants with Sinopharm…
- Trial name
- NCT05308602
- Testing
- SCTV01C, SCTV01E, mRNA vaccine manufactured by Pfizer or Moderna
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Coronavirus Disease-2019 (COVID-19)
Safety of TY027, a Treatment for COVID-19, in Humans
The emergence and rapid spread of the coronavirus disease 2019 (COVID-19) since December 2019 across 188 countries globally has become a major public health crisis.
- Trial name
- NCT04429529
- Testing
- TY027, 0.9% Saline
- Where
- Singapore
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Tychan Pte Ltd.
COVID-19
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
Phase 1 To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 Phase 2 To evaluate the…
- Trial name
- NCT04425629
- Testing
- casirivimab+imdevimab combination therapy
- Where
- 114 sites in United States, Mexico and 1 more
- Volunteers
- 10,078 people
- Sponsor
- Regeneron Pharmaceuticals
SARS-CoV-2 Infection, COVID-19
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
The study is a randomized, double-blind, positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E compared with Comirnaty.
- Trial name
- NCT05329051
- Testing
- SCTV01E, Comirnaty
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Covid19, Sars-CoV-2 Infection
Performance Study of SONA Saliva C-19 Rapid Test
The Sona Saliva C-19 Rapid Test is a bioassay intended for rapid point-of-care detection of the SARS-CoV-2 virus. Performance of the Sona Saliva C-19 Rapid Test assay will be assessed by comparison to a RT-PCR reference method
- Conditions
- Covid19, Sars-CoV-2 Infection, Corona Virus Infection
- Trial name
- NCT04877002
- Testing
- Sona Saliva C-19 Rapid Test
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Sona Nanotech Inc
Acute Lung Injury, ALI
A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
The aim of this study will test the safety, tolerability, and efficacy of RLS-0071 for approximately 28 days in comparison to a placebo control in patients with acute lung injury due to COVID-19 pneumonia in early respiratory…
- Conditions
- Acute Lung Injury, ALI, COVID-19
- Trial name
- NCT04574869
- Testing
- RLS-0071 10 mg/kg, RLS-0071 40 mg/kg
- Where
- United States
- Sponsor
- ReAlta Life Sciences, Inc.
Depression, COVID-19
Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression After SARS-CoV-2 (TELESPHOR)
This is a multi-centre, observational, non-interventional study, which will prospectively collect clinical and socio-demographic data from patients with depression occurred after COVID 19 in real clinical settings during 8 weeks…
- Trial name
- TELESPHOR (NCT05323994)
- Where
- Russia
- Volunteers
- 104 people
- Sponsor
- Servier Russia
COVID-19 Lower Respiratory Infection
Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)
This study will assess the safety and immunogenicity of AG0302-COVID19 in healthy volunteers.
- Trial name
- NCT04993586
- Testing
- AG0302-COVID19 for Intramuscular Injection, AG0302-COVID19 for Intradermal Injection
- Where
- 6 sites in Japan
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- AnGes, Inc.
SARS-CoV-2 Infection
Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）
The objective of this study is to evaluate the safety and immunogenicity of MT-2766 in Japanese adults.
- Trial name
- NCT05065619
- Testing
- MT-2766 High dose (3.75 µg), MT-2766 Low dose
- Where
- 3 sites in Japan
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Medicago
SARS-CoV-2 Infection
A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection
This was a Phase 2/3 study to assess the efficacy about therapeutic effect of CT-P59 to the mild to moderate SARS-CoV-2 infected patients and the safety during after study drug injection.
- Trial name
- NCT04602000
- Testing
- CT-P59
- Where
- South Korea
- Volunteers
- 1,642 people
- Sponsor
- Celltrion
SARS-CoV 2, COVID-19
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Study objective is to evaluate the efficacy of the combination of masitinib and isoquercetin in adult hospitalized patients with moderate and severe COVID-19.
- Conditions
- SARS-CoV 2, COVID-19, Coronavirus Disease 2019
- Trial name
- NCT04622865
- Testing
- Masitinib, Isoquercetin, Best Supportive Care
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- AB Science
COVID-19
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have…
- Trial name
- NCT05636319
- Testing
- ABO1020
- Where
- 25 sites in Indonesia, Pakistan and 2 more
- Volunteers
- 14,168 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.